Chemical bonding

WPI-MANA: Reaping Benefits of Collaboration and Integration

Retrieved on: 
Monday, July 26, 2021
Physical sciences, Natural sciences, Chemistry, Matter, Molecule, Organic chemistry, Quantum chemistry, Chemical bonding, Materials science

Four of the key researchers in these programs -- Dr. Waka Nakanishi and Dr. Ayako Nakata in the Theory-Experiment Pairing Program, and Dr. Toshikaze Kariyado and Dr. Takuya Iwasaki in the Challenging Research Program -- sat down with MANA e-Bulletin to discuss their work and their experience with these programs.

Key Points: 
  • Nakanishi: In organic chemistry, we create organic molecules in the desired form by connecting carbon atoms.
  • Since their structure is directly related to their functions, I focus on realizing functions by designing molecules.
  • Therefore, we developed a program called CONQUEST to determine the state of systems and molecules containing many atoms.
  • Experiments that look at the shape and function of single molecules are still in their infancy...
    Click the following link to read the full story.

WPI-MANA: Reaping Benefits of Collaboration and Integration

Retrieved on: 
Monday, July 26, 2021
Physical sciences, Natural sciences, Chemistry, Matter, Molecule, Organic chemistry, Quantum chemistry, Chemical bonding, Materials science

Four of the key researchers in these programs -- Dr. Waka Nakanishi and Dr. Ayako Nakata in the Theory-Experiment Pairing Program, and Dr. Toshikaze Kariyado and Dr. Takuya Iwasaki in the Challenging Research Program -- sat down with MANA e-Bulletin to discuss their work and their experience with these programs.

Key Points: 
  • Nakanishi: In organic chemistry, we create organic molecules in the desired form by connecting carbon atoms.
  • Since their structure is directly related to their functions, I focus on realizing functions by designing molecules.
  • Therefore, we developed a program called CONQUEST to determine the state of systems and molecules containing many atoms.
  • Experiments that look at the shape and function of single molecules are still in their infancy...
    Click the following link to read the full story.

Kanazawa University research: Solvent effects of siloxanes on donor-acceptor interactions

Retrieved on: 
Tuesday, May 11, 2021
Physical sciences, Natural sciences, Chemistry, Supramolecular chemistry, Chemical bonding, Non-covalent interaction, Supramolecular polymer, Pi interaction

b'KANAZAWA, Japan, May 11, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Chemical Communications how solvents influence the strength of donoracceptor interactions.

Key Points: 
  • b'KANAZAWA, Japan, May 11, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Chemical Communications how solvents influence the strength of donoracceptor interactions.
  • The aromatic DA interactions are widely used for building supramolecular structures, which are assembly of molecules formed by non-covalent bonds like building blocks.
  • The stability and smart properties of supramolecular architectures formed by D-A interactions depend on characteristics of the DA interactions in various circumstances.
  • Poly(dimethylsiloxane) and oligo(dimethylsiloxane) solvent effects on aromatic donoracceptor interactions, Chem.

Kanazawa University research: Solvent effects of siloxanes on donor-acceptor interactions

Retrieved on: 
Tuesday, May 11, 2021
Physical sciences, Natural sciences, Chemistry, Supramolecular chemistry, Chemical bonding, Non-covalent interaction, Supramolecular polymer, Pi interaction

b'KANAZAWA, Japan, May 11, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Chemical Communications how solvents influence the strength of donoracceptor interactions.

Key Points: 
  • b'KANAZAWA, Japan, May 11, 2021 /PRNewswire/ -- Researchers at Kanazawa University report in Chemical Communications how solvents influence the strength of donoracceptor interactions.
  • The aromatic DA interactions are widely used for building supramolecular structures, which are assembly of molecules formed by non-covalent bonds like building blocks.
  • The stability and smart properties of supramolecular architectures formed by D-A interactions depend on characteristics of the DA interactions in various circumstances.
  • Poly(dimethylsiloxane) and oligo(dimethylsiloxane) solvent effects on aromatic donoracceptor interactions, Chem.

NJ Bio Moves Headquarters to Princeton, New Jersey

Retrieved on: 
Tuesday, May 4, 2021
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Natural sciences, Biochemistry, Bioconjugation, Chemical bonding, Bristol Myers Squibb, Life sciences, Biotechnology

View the full release here: https://www.businesswire.com/news/home/20210504005811/en/\nNew Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ (Photo: Business Wire)\nThe 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb .

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210504005811/en/\nNew Headquarters for NJ Bio at 350 Carter Road, Princeton, NJ (Photo: Business Wire)\nThe 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb .
  • NJ Bio will continue to operate its facility in Bristol, PA, with plans for future growth at that site, including GMP manufacturing capabilities for small molecules as well as bioconjugation.\n\xe2\x80\x9cOn behalf of the board of directors and senior management at NJ Bio, I am excited to announce this move,\xe2\x80\x9d said Nareshkumar Jain , Ph.D., President and CEO of NJ Bio.
  • \xe2\x80\x9cOur expansion to this advanced facility demonstrates the rapid growth of NJ Bio in just over two years.
  • NJ Bio also offers expertise in flow chemistry and process development and provides innovative solutions for large-scale continuous manufacturing needs.

Comparison of Hybrid LCMS & Ligand Binding Assays for Bioanalysis, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 5, 2021
Natural sciences, Physical sciences, Chemistry, Chemical bonding, Analytical chemistry, Bioanalysis, Pharmacokinetics, Toxicology, Ligand binding assay, Ligand, Assay

TORONTO, April 5, 2021 /PRNewswire-PRWeb/ -- Historically, bioanalytical support for large molecule development has utilized ligand binding (LBA) technologies.

Key Points: 
  • TORONTO, April 5, 2021 /PRNewswire-PRWeb/ -- Historically, bioanalytical support for large molecule development has utilized ligand binding (LBA) technologies.
  • Hybrid mass spectrometry only requires one reagent for enrichment and this reagent does not need to be extremely selective.
  • In the past, our ligand binding team provided the majority of our large molecule bioanalysis support.
  • For more information, or to register for this event, visit Comparison of Hybrid LCMS & Ligand Binding Assays for Bioanalysis.

Ligand Provides Highlights from Today’s Investor Day Event

Retrieved on: 
Tuesday, October 20, 2020
Biotechnology, Health, Science, Pharmaceutical, Research, Natural sciences, Physical sciences, Chemistry, Chemical bonding, Coordination chemistry, Proteins, Ligand Pharmaceuticals, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at todays virtual Investor Day event its senior management reviewed recent business progress and provided a financial growth outlook.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at todays virtual Investor Day event its senior management reviewed recent business progress and provided a financial growth outlook.
  • Highlights of todays presentations include the following:
    Business model and growth drivers:
    Management reviewed Ligands business model and the ongoing diversification of its portfolio.
  • Ligand reported that it is positioned to continue OmniAbs best-in-class status with recent innovation and technology offering expansion.
  • Ligand disclaims responsibility for any statement by a person other than its employees and the views expressed by persons other than Ligand employees do not necessarily reflect the views of Ligand.

Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform

Retrieved on: 
Thursday, October 8, 2020
Branches of biology, Proteins, Biology, Natural sciences, Biochemistry, Bioconjugation, Chemical bonding, Cyclin-dependent kinase 9, P-TEFb, Antibody-drug conjugate

Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer.

Key Points: 
  • Under the terms of the license agreement, Vincera will in-license VIP152 (formerly BAY 1251152), a clinical-stage, highly selective, positive transcription elongation factor b (PTEFb)/cyclin-dependent kinase 9 (CDK9) inhibitor for the treatment of cancer.
  • Additionally, Vincera will receive assets and license technology for a preclinical bioconjugation platform to address the limitations of small-molecule and antibody-drug conjugates in oncology.
  • Dr. Hamdy continued, In addition to our planned clinical program, we intend to advance, in parallel, the development of our preclinical bioconjugation platform.
  • In exchange for this license, Vincera will pay Bayer an upfront license fee and development and commercial sales milestone payments.

LBA and Hybrid LCMS Quantitation of Biotherapeutics and Biomarkers, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, June 22, 2020
Branches of biology, Natural sciences, Physical sciences, Chemical bonding, Chemical pathology, LBA, Ligand binding assay, Ligand, Biomarker, Mass spectrometry, LCMS

However, the use of mass spectrometry in this field has gained a lot of momentum in the last several years.

Key Points: 
  • However, the use of mass spectrometry in this field has gained a lot of momentum in the last several years.
  • This now necessitates the question "How do you choose which approach to use (LBA or MS)?"
  • For the LBA, we will discuss the different types of ligand binding assays, answers to common questions that can lead to performing LBA vs. hybrid LCMS and some advantages of LBA over LCMS methodologies.
  • For more information or to register for this event, visit LBA and Hybrid LCMS Quantitation of Biotherapeutics and Biomarkers .

Ligand CEO Issues Letter to Captisol Customers

Retrieved on: 
Monday, June 1, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Physical sciences, Natural sciences, Chemistry, Chemical bonding, NASDAQ, Chelating agents, Coordination chemistry, Proteins, Ligand Pharmaceuticals, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligands Captisol customers.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligands Captisol customers.
  • The full text of that letter is as follows:
    To Our Valued Captisol Customers,
    Ligand is in a period of momentous planning and scale-up.
  • I want to update you as to where Ligand stands in fulfilling our commitment to all our Captisol customers and discuss our plans to increase manufacturing capacity.
  • Over the years Ligand has provided Captisol to more than a thousand organizations for an array of medical uses.